Seres Therapeutics, Inc. (NASDAQ:MCRB) Short Interest Down 17.8% in July

Seres Therapeutics, Inc. (NASDAQ:MCRB) was the target of a large decline in short interest in the month of July. As of July 15th, there was short interest totalling 17,000,000 shares, a decline of 17.8% from the June 30th total of 20,690,000 shares. Based on an average daily volume of 4,960,000 shares, the days-to-cover ratio is presently 3.4 days.

Seres Therapeutics Price Performance

MCRB stock traded up $0.11 during midday trading on Monday, hitting $1.43. The company’s stock had a trading volume of 2,298,819 shares, compared to its average volume of 4,716,511. The company’s fifty day moving average price is $0.94 and its 200 day moving average price is $0.95. Seres Therapeutics has a twelve month low of $0.54 and a twelve month high of $5.29. The stock has a market capitalization of $216.57 million, a P/E ratio of -2.38 and a beta of 1.98.

Seres Therapeutics (NASDAQ:MCRB) last released its earnings results on Wednesday, May 8th. The biotechnology company reported ($0.27) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.36) by $0.09. Equities analysts expect that Seres Therapeutics will post -1.03 EPS for the current fiscal year.

Analyst Ratings Changes

Several equities research analysts have recently issued reports on MCRB shares. Canaccord Genuity Group lowered their price objective on shares of Seres Therapeutics from $15.00 to $10.00 and set a “buy” rating for the company in a research report on Friday, June 7th. Oppenheimer reissued a “market perform” rating on shares of Seres Therapeutics in a research note on Friday, June 7th. Chardan Capital reduced their price objective on Seres Therapeutics from $8.00 to $6.00 and set a “buy” rating for the company in a research report on Wednesday, May 8th. Finally, StockNews.com upgraded Seres Therapeutics from a “sell” rating to a “hold” rating in a report on Tuesday, July 9th.

Institutional Investors Weigh In On Seres Therapeutics

Several large investors have recently made changes to their positions in MCRB. Vanguard Group Inc. raised its position in Seres Therapeutics by 12.1% during the first quarter. Vanguard Group Inc. now owns 6,734,821 shares of the biotechnology company’s stock worth $5,213,000 after acquiring an additional 729,514 shares in the last quarter. Handelsbanken Fonder AB lifted its stake in Seres Therapeutics by 10.0% in the 4th quarter. Handelsbanken Fonder AB now owns 1,100,000 shares of the biotechnology company’s stock valued at $1,540,000 after purchasing an additional 100,000 shares during the last quarter. Pennant Investors LP bought a new position in Seres Therapeutics during the fourth quarter worth about $409,000. Virtu Financial LLC acquired a new position in Seres Therapeutics during the first quarter worth approximately $73,000. Finally, SG Americas Securities LLC acquired a new stake in shares of Seres Therapeutics in the fourth quarter valued at approximately $73,000. Institutional investors and hedge funds own 59.34% of the company’s stock.

Seres Therapeutics Company Profile

Seres Therapeutics, Inc, a microbiome therapeutics company, develop microbiome therapeutics to treat the modulation of the colonic microbiome. It develops a novel class of biological drugs that are designed to treat by modulating the microbiome to restore health by repairing the function of a disrupted microbiome to a non-disease state.